Randomized clinical trial describing PFS and MRD data in >50 patients, using NGF and sequencing methods with a reported minimum sensitivity of 10−5, in Medline articles and ASCO/ASH/EHA/IMS abstracts published until 2 December 2022.
| Clinical trial (phase) . | NCT . | Disease setting . | Randomization . | MRD method . | MRD-ve rates (%) . | Median PFS (mo) . | Reference . |
|---|---|---|---|---|---|---|---|
| ATLAS (3) | NCT02659293 | NDTE | KRD vs R alone | NGS | 53% vs 31% | 59.1 vs 41.4 | 1 |
| CASSIOPEIA (3) | NCT02541383 | NDTE | DaraVTD vs VTD | NGF | 64% vs 43.5% | NR vs 51.5 | 6 |
| DETERMINATION (3) | NCT01208662 | NDTE | VRD-ASCT vs VRD alone | NGS | 13% vs 12% | 67.5 vs 46.2 | 2 |
| GEM2012MENOS65 (3) | NCT01916252 | NDTE | VRD-BuMel vs VRD-Mel | NGF | 58% vs 55.5% | NR vs 75.3 | 4 |
| GRIFFIN (2) | NCT02874742 | NDTE | DaraVRD vs VRD | NGS | 64% vs 30% | NR vs NR | 5 |
| IFM 2009 (3) | NCT01191060 | NDTE | VRD-ASCT vs VRD alone | NGS | 21% vs 15% | 50.0 vs 36.0 | 3 |
| ALCYONE (3) | NCT02195479 | NDTI | DaraVMP vs VMP | NGS | 28% vs 7% | 36.4 vs 19.3 | 8 |
| CLARION (3) | NCT01818752 | NDTI | KMP vs VMP | NGF | 5% vs 5% | 22.3 vs 22.1 | 9 |
| MAIA (3) | NCT02252172 | NDTI | DaraRD vs RD | NGS | 31% vs 10% | 62.0 vs 34.3 | 7 |
| APOLLO (3) | NCT03180736 | RRMM | DaraPD vs PD | NGS | 9% vs 2% | 12.4 vs 6.9 | 15 |
| BOSTON (3) | NCT03110562 | RRMM | SelVD vs VD | NGF | 5% vs 4% | 13.9 vs 9.5 | 16 |
| CANDOR (3) | NCT03158688 | RRMM | DaraKD vs KD | NGS | 18% vs 4% | 28.6 vs 15.2 | 12 |
| CASTOR(3) | NCT02136134 | RRMM | DaraVD vs VD | NGS | 15% vs 2% | 16.7 vs 7.1 | 11 |
| IKEMA (3) | NCT03275285 | RRMM | IsaKD vs KD | NGS | 30% vs 13% | NR vs 19.2 | 13 |
| POLLUX (3) | NCT02076009 | RRMM | DaraRD vs RD | NGS | 33% vs 17% | 45.0 vs 17.5 | 10 |
| Clinical trial (phase) . | NCT . | Disease setting . | Randomization . | MRD method . | MRD-ve rates (%) . | Median PFS (mo) . | Reference . |
|---|---|---|---|---|---|---|---|
| ATLAS (3) | NCT02659293 | NDTE | KRD vs R alone | NGS | 53% vs 31% | 59.1 vs 41.4 | 1 |
| CASSIOPEIA (3) | NCT02541383 | NDTE | DaraVTD vs VTD | NGF | 64% vs 43.5% | NR vs 51.5 | 6 |
| DETERMINATION (3) | NCT01208662 | NDTE | VRD-ASCT vs VRD alone | NGS | 13% vs 12% | 67.5 vs 46.2 | 2 |
| GEM2012MENOS65 (3) | NCT01916252 | NDTE | VRD-BuMel vs VRD-Mel | NGF | 58% vs 55.5% | NR vs 75.3 | 4 |
| GRIFFIN (2) | NCT02874742 | NDTE | DaraVRD vs VRD | NGS | 64% vs 30% | NR vs NR | 5 |
| IFM 2009 (3) | NCT01191060 | NDTE | VRD-ASCT vs VRD alone | NGS | 21% vs 15% | 50.0 vs 36.0 | 3 |
| ALCYONE (3) | NCT02195479 | NDTI | DaraVMP vs VMP | NGS | 28% vs 7% | 36.4 vs 19.3 | 8 |
| CLARION (3) | NCT01818752 | NDTI | KMP vs VMP | NGF | 5% vs 5% | 22.3 vs 22.1 | 9 |
| MAIA (3) | NCT02252172 | NDTI | DaraRD vs RD | NGS | 31% vs 10% | 62.0 vs 34.3 | 7 |
| APOLLO (3) | NCT03180736 | RRMM | DaraPD vs PD | NGS | 9% vs 2% | 12.4 vs 6.9 | 15 |
| BOSTON (3) | NCT03110562 | RRMM | SelVD vs VD | NGF | 5% vs 4% | 13.9 vs 9.5 | 16 |
| CANDOR (3) | NCT03158688 | RRMM | DaraKD vs KD | NGS | 18% vs 4% | 28.6 vs 15.2 | 12 |
| CASTOR(3) | NCT02136134 | RRMM | DaraVD vs VD | NGS | 15% vs 2% | 16.7 vs 7.1 | 11 |
| IKEMA (3) | NCT03275285 | RRMM | IsaKD vs KD | NGS | 30% vs 13% | NR vs 19.2 | 13 |
| POLLUX (3) | NCT02076009 | RRMM | DaraRD vs RD | NGS | 33% vs 17% | 45.0 vs 17.5 | 10 |
DaraKD, daratumumab-carfilzomib-dexamethasone; DaraPD, daratumumab-pomalidomide-dexamethasone; DaraRD, daratumumab-lenalidomide-dexamethasone; DaraVD, daratumumab-bortezomib-dexamethasone; DaraVMP, daratumumab-bortezomib-melphalan-prednisone; DaraVRD, daratumumab-bortezomib-lenalidomide-dexamethasone; DaraVTD, daratumumab-bortezomib-thalidomide-dexamethasone; IsaKD, isatuximab-carfilzomib-dexamethasone; KD, carfilzomib-dexamethasone; KRD12, carfilzomib-lenalidomide-dexamethasone (12 cycles); NCT, National Clinical Trial (Clinicaltrials.gov Identification Number); NGF, next-generation flow; NGS, next-generation sequencing; NR, not reached; PD, pomalidomide-dexamethasone; RD, lenalidomide-dexamethasone; SelVD, selinexor-bortezomib-dexamethasone; VD, bortezomib-dexamethasone; VMP, bortezomib-melphalan-prednisone; VRD, bortezomib-lenalidomide-dexamethasone; VRd-BuMel, bortezomib-lenalidomide-dexamethasone-busulfan-melphalan; VRd-Mel, bortezomib-lenalidomide-dexamethasone-melphalan; VTD, bortezomib-thalidomide-dexamethasone.